Altered cell cycle regulation helps stem-like carcinoma cells resist apoptosis
© Chappell and Dalton; licensee BioMed Central Ltd. 2010
Received: 19 April 2010
Accepted: 17 May 2010
Published: 25 May 2010
Reemergence of carcinomas following chemotherapy and/or radiotherapy is not well understood, but a recent study in BMC Cancer suggests that resistance to apoptosis resulting from altered cell cycle regulation is crucial.
See research article: http://biomedcentral.com/1471-2407/10/166
Tumor recurrence: a poorly understood phenomenon
Typically, when a tumor is discovered, patients are treated with a combination of surgery, chemotherapy and radiotherapy, depending on the location and type of cancer. The goal of these treatments is to completely remove or destroy any cancerous cell growth. Often these treatments are met with apparent success, as indicated by shrinkage in tumor volume. Tumor reemergence is, however, frequent  but this phenomenon is poorly understood. It is not even clear whether one common factor underpins the ability of many different tumor types to reemerge after a remission period.
This general problem has led researchers to investigate possible explanations for tumor recurrence. One idea is that tumor heterogeneity is derived from a cell capable of generating many different cell types. This has led to the prediction that at least some tumors arise from a cell with stem-like properties. It is unclear, however, whether this would be a naturally occurring multipotent stem cell or a cell that acquires stem-like properties following mutational events, for example. Although the origin of these stem-like cells is contentious, the term cancer stem cell (CSCs) is often applied and will be used here. CSCs are currently a 'hot' topic because their potential properties are consistent with a tumor-initiating cell that might be able to regenerate the complexity of an entire tumor . The obvious question, however, is how CSCs could survive genotoxic damage under conditions in which other tumor cells die. The answer to this question could be crucial for the development of new tumor therapeutics.
Subpopulations with increased apoptotic resistance
Understanding the mechanisms underpinning resistance to apoptosis following chemo- or radiotherapy has been prompted by the promise that this could lead to a new generation of therapeutic approaches. Several reports indicate that CSCs can pump out toxins through specific chemical efflux pathways . These cells are often resistant to DNA damage and show greater DNA repair capacity than their non-stem-like counterparts . New findings reported in BMC Cancer  reveal that altered cell cycle regulation could also have a role in apoptotic resistance in at least some CSCs.
Epithelial tumors are the most commonly diagnosed cancer type  and are therefore a high priority in terms of therapeutic development. Mackenzie and colleagues  address the problem by focusing on human head and neck squamous cell carcinomas (HNSCCs). HNSCCs are epithelial tumors with a high rate of tumor recurrence following initial treatment , making them a logical choice for investigation of apoptotic resistance mechanisms. As in previous studies, subpopulations of cells with stem-like properties were isolated by fluorescence-activated cell sorting (FACS), using the cell surface glycoprotein CD44 as a marker. Assays comparing in vitro 'tumor sphere' formation and clonogenicity demonstrated that cells expressing high levels of CD44 (CD44high) with a highly compact, holoclone colony morphology have stem-like characteristics of CSCs.
Mackenzie and colleagues  show that CD44high cells are less sensitive to several chemical apoptosis-inducing agents than are CD44low cells. Although previous studies showed that ABC transporters are expressed at high levels in these cells, the ability to pump out foreign chemicals is not the entire story when it comes to apoptotic resistance . The current study , for example, shows that treatment with chemotherapeutics and radiotherapy is less effective at promoting apoptosis in CD44high cells, thereby arguing against a role for ABC transporters.
Increased apoptotic resistance is associated with a G2/M phase cell cycle block
What, then, is the reason behind the observed apoptotic insensitivity in CD44high CSCs? Insight into this question came from observations made by Mackenzie and colleagues , who showed that CD44high subpopulations of epithelial, breast and prostate carcinoma cells have a consistently higher proportion of cells in the G2 phase. Using pulse chase experiments involving 5-iodo-2'-deoxyuridine (IdU) labeling of cells in S phase followed by FACS analysis, cell cycle progression was then tracked through G2 back into G1. The conclusion of this study is that CD44high cells spent a consistently longer time in G2.
Future directions and therapeutic value
Mackenzie and colleagues  have revealed important additional information about the mechanisms by which tumors evade current therapeutic treatments. Of interest is the finding that CD44high subpopulations, displaying an increase in apoptotic resistance and a longer G2 phase, were also found in normal oral keratinocytes. This observation is a strong argument for the idea that a small subpopulation of cells with inherent stem-like properties naturally occurs and is not solely a product of malignant transformation.
More importantly, the authors  demonstrate that in addition to the efficient efflux and DNA repair mechanisms, CSCs also have an altered cell cycle program. Further biochemical characterization of these cells may explain how the G2/M checkpoint is activated and exactly how a longer G2 phase is conferring a survival advantage in cooperation with previously known mechanisms. A key question is what signaling pathways activate checkpoints in CD44high cells. This could provide insight into what should be targeted for drug development. Prematurely releasing these cells from their prolonged G2 phase and G2/M block could trigger apoptosis instead of enhanced survival and tumor relapse. Therefore, it may be advantageous for future therapeutic treatments to target the Chk proteins or their upstream activators. In combination with modern chemical or radiation-based therapies, tumor elimination without relapse is an exciting possibility.
- La Vecchia C, Lucchini F, Negri E, Levi F: Trends in oral cancer mortality in Europe. Oral Oncol. 2004, 40: 433-439. 10.1016/j.oraloncology.2003.09.013.View ArticlePubMedGoogle Scholar
- Sell S: Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol. 2004, 51: 1-28. 10.1016/j.critrevonc.2004.04.007.View ArticlePubMedGoogle Scholar
- Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006, 5: 67-10.1186/1476-4598-5-67.PubMed CentralView ArticlePubMedGoogle Scholar
- Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006, 444: 756-760. 10.1038/nature05236.View ArticlePubMedGoogle Scholar
- Harper LJ, Costea DE, Gammon L, Fazil B, Biddle A, Mackenzie IC: Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase associated with apoptotic resitance. BMC Cancer. 2010, 10: 166-10.1186/1471-2407-10-166.PubMed CentralView ArticlePubMedGoogle Scholar
- National Cancer Institute: Common Cancer Types. http://www.cancer.gov/cancertopics/commoncancers,
- Matta A, Ralhan R: Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol. 2009, 1: 6-10.1186/1758-3284-1-6.PubMed CentralView ArticlePubMedGoogle Scholar
- Hirschmann-Jax C, Foster AE, Wulf GG, Goodell MA, Brenner MK: A distinct "side population" of cells in human tumor cells: implications for tumor biology and therapy. Cell Cycle. 2005, 4: 203-205.View ArticlePubMedGoogle Scholar
- Wei Q, Li L, Chen D: DNA Repair, Genetic Instability, and Cancer. 2007, Singapore: World ScientificView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.